Darrell Hoi-San Tan

Darrell Hoi-San Tan

Auto-generated profile, based on publicly available information

Darrell Hoi-San Tan

Division of Infectious Diseases St. Michael's Hospital Toronto Ontario Canada

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2017 in Canadian Medical Association Journal
Verified
Journal Article
Open access
PDF file
DTDarrell H. S. Tan
Darrell H. S. Tan
MHMark W. Hull
Mark W. Hull
DYDeborah Yoong
Deborah Yoong
CTCécile Tremblay
Cécile Tremblay
POPatrick O’bYrne
Patrick O’bYrne
SSStephen Shafran
Stephen Shafran
KEY POINTS New HIV infections occur every year in Canada,[1][1] highlighting the need for integrated prevention programs. Pre-exposure prophylaxis (PrEP) and nonoccupational postexposure prophylaxis (nPEP) are two important strategies for preventing HIV that should be considered standard of care and

13 February 2019 in Harm Reduction Journal
Verified
Journal Article
Open access
PDF file
SCSoo Chan Carusone
Soo Chan Carusone
AGAdrian Guta
Adrian Guta
SRSamantha Robinson
Samantha Robinson
DTDarrell H. Tan
Darrell H. Tan
CCCurtis Cooper
Curtis Cooper
CSCarol Strike
Carol Strike
Drug use is associated with increased morbidity and mortality but people who use drugs experience significant barriers to care. Data are needed about the care experiences of people who use drugs to inform interventions and quality improvement initiatives. The objective of this study is to describe and characterize the experience of acute care for people who use drugs. We conducted a qualitative descriptive study. We recruited people with a history of active drug use at the time of an admission to an acute care hospital, who were living with HIV or hepatitis C, in Toronto and Ottawa, Canada. Data were collected in 2014 and 2015 through semi-structured interviews, audio-recorded and transcribed, and analyzed thematically. Twenty-four adults (18 men, 6 women) participated. Participants predominantly recounted experiences of stigma and challenges accessing care. We present the identified themes in two overarching domains of interest: perceived effect of drug use on hospital care and impact of care experiences on future healthcare interactions. Participants described significant barriers to pain management, often resulting in inconsistent and inadequate pain management. They described various strategies to navigate access and receipt of healthcare from being “an easy patient” to self-advocacy. Negative experiences influenced their willingness to seek care, often resulting in delayed care seeking and targeting of certain hospitals. Drug use was experienced as a barrier at all stages of hospital care. Interventions to decrease stigma and improve our consistency and approach to pain management are necessary to improve the quality of care and care experiences of those who use drugs.

1 January 2016 in Journal of the International AIDS Society
Verified
Journal Article
Open access
PDF file
JWJames Wilton
James Wilton
TKTaylor Kain
Taylor Kain
SFShawn Fowler
Shawn Fowler
THTrevor A Hart
Trevor A Hart
TGTroy Grennan
Troy Grennan
DTDarrell Hs Tan
Darrell Hs Tan
Introduction: Identifying appropriate pre‐exposure prophylaxis (PrEP) candidates is a challenge in planning for the safe and effective roll‐out of this strategy. We explored the use of a validated HIV risk screening tool, HIV Incidence Risk Index for Men who have Sex with Men (HIRI‐MSM), to identify “optimal” candidates among MSM testing at a busy sexual health clinic's community testing sites in Toronto, Canada.Methods: Between November 2014 and April 2015, we surveyed MSM undergoing anonymous HIV testing at community testing sites in Toronto, Canada, to quantify “optimal” candidates for scaling up PrEP roll‐out, defined as being at high objective HIV risk (scoring ≥10 on the HIRI‐MSM), perceiving oneself at moderate‐to‐high HIV risk and being willing to use PrEP. Cascades were constructed to identify barriers to broader PrEP uptake. The association between HIRI‐MSM score and both willingness to use PrEP and perceived HIV risk were explored in separate multivariable logistic regression analyses.Results: Of 420 respondents, 64.4% were objectively at high risk, 52.5% were willing to use PrEP and 27.2% perceived themselves at moderate‐to‐high HIV risk. Only 16.4% were “optimal” candidates. Higher HIRI‐MSM scores were positively associated with both willingness to use PrEP (aOR=1.7 per 10 score increase, 95%CI=1.3–2.2) and moderate‐to‐high perceived HIV risk (aOR=1.7 per 10 score increase, 95%CI=1.2–2.3). The proportion of men who were “optimal” candidates increased to 42.9% when the objective HIV risk cut‐off was changed to top quartile of HIRI‐MSM scores (≥26). In our full cascade, a very low proportion (5.3%) of MSM surveyed could potentially benefit from PrEP under current conditions. The greatest barrier in the cascade was low perception of HIV risk among high‐risk men, but considerable numbers were also lost in downstream cascade steps. Of men at high objective HIV risk, 68.3% did not perceive themselves to be at moderate‐to‐high HIV risk, 23.6% were unaware of PrEP, 40.1% were not willing to use PrEP, 47.6% lacked a family physician with whom they felt comfortable discussing sexual health, and 31.6% had no means to cover the cost of PrEP.Conclusions: A higher HIRI‐MSM cut‐off may be helpful for identifying candidates for PrEP scale‐up. Improving engagement in the PrEP cascade will require interventions to simultaneously address multiple barriers.

20 August 2015 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
OTon behalf of the OHTN Cohort Study Team
on behalf of the OHTN Cohort Study Team
ABAnn N. Burchell
Ann N. Burchell
VAVanessa G. Allen
Vanessa G. Allen
SGSandra L. Gardner
Sandra L. Gardner
VMVeronika Moravan
Veronika Moravan
SRSean B. Rourke
Sean B. Rourke
The re-emergence of syphilis among HIV-positive gay and other men who have sex with men (MSM) requires vigilance. We estimated incidence of and risk factors for first and subsequent syphilis diagnoses among MSM in HIV care in Ontario, Canada. We analyzed data from 2,280 MSM under follow-up from 2006 to 2010 in the Ontario HIV Treatment Network Cohort Study (OCS), a multi-site clinical cohort. We obtained syphilis serology results via record linkage with the provincial public health laboratory. Rates were calculated using Poisson regression. First syphilis diagnoses occurred at a rate of 2.0 per 100 person-years (95 % CI 1.7, 2.4; 121 cases) whereas the re-diagnosis rate was 7.5 per 100 person-years (95 % CI 6.3, 8.8; 136 cases). We observed higher rates over time and among men who were aged <30 years, receiving care in the two largest urban centers, or had a previous syphilis diagnosis. Syphilis diagnosis was less common among Indigenous men, men with higher CD4 cell counts, and, for first diagnoses only, among men with less than high school education. Compared to reported cases in the general male population, incidence of a new syphilis diagnosis was over 300 times greater among HIV-positive MSM but year-to-year changes reflected provincial trends. Re-diagnosis was common, suggesting treatment failure or re-infection. Novel syphilis control efforts are needed among HIV-positive MSM.

15 February 2022 in JAC-Antimicrobial Resistance
Verified
Journal Article
Open access
PDF file
RTRobinson Truong
Robinson Truong
VTVincent Tang
Vincent Tang
TGTroy Grennan
Troy Grennan
DTDarrell H. S. Tan
Darrell H. S. Tan
There is interest in doxycycline as prophylaxis against sexually transmitted infections (STIs), but concern about antimicrobial resistance (AMR). We conducted a systematic review (CRD42021273301) of the impact of oral tetracycline-class antibiotics on AMR in normal flora. We searched MEDLINE, EMBASE, the Cochrane Library (1940–2021) and conference proceedings (2014–21) for randomized controlled trials in adults comparing daily oral tetracycline-class antibiotics to non-tetracycline controls. The primary outcome was AMR to tetracyclines; secondary outcomes included resistance to non-tetracyclines. Data were inappropriate for meta-analysis, so we analysed findings descriptively. Our search yielded 6265 abstracts of which 7 articles fulfilled inclusion criteria. Most were at moderate/high risk of bias, generally due to inadequate methodologic reporting. Studies used doxycycline, tetracycline, oxytetracycline or minocycline for 2–18 weeks. Most observed an increased burden of tetracycline resistance, including in subgingival (n = 3 studies), gastrointestinal (n = 2) and upper respiratory tract (n = 1) flora; one study of skin flora found no change in tetracycline-resistant Propionibacterium species after 18 weeks of oxytetracycline/minocycline. Four studies reassessed AMR at 2–50 weeks post-intervention and reported varying degrees of resistance. Three articles reported on the prevalence of non-tetracycline AMR after doxycycline prophylaxis, of which one found a transient increase among gastrointestinal Escherichia coli; the other two showed no difference from control. Although the effects are modest and transient, limited data from small prospective studies may suggest that oral tetracyclines for 2–18 weeks increase resistance in subgingival, gastrointestinal and upper respiratory tract flora. STI prophylaxis trials should include AMR in commensal bacteria as study outcomes.

18 August 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MSMalika Sharma
Malika Sharma
JWJames Wilton
James Wilton
HSHeather Senn
Heather Senn
SFShawn Fowler
Shawn Fowler
DTDarrell H. S. Tan
Darrell H. S. Tan
Recent evidence has demonstrated the efficacy of pre-exposure prophylaxis (PrEP) for HIV prevention, but concerns persist around its use. Little is known about Canadian physicians' knowledge of and willingness to prescribe PrEP. We disseminated an online survey to Canadian family, infectious disease, internal medicine, and public health physicians between September 2012–June 2013 to determine willingness to prescribe PrEP. Criteria for analysis were met by 86 surveys. 45.9% of participants felt “very familiar” with PrEP, 49.4% felt that PrEP should be approved by Health Canada, and 45.4% of respondents were willing to prescribe PrEP. Self-identifying as an HIV expert (odds ratio, OR = 4.1, 95% confidence interval, CI = 1.6–10.2), familiarity with PrEP (OR = 5.0, 95%CI = 1.3–19.0) and having been asked by patients about PrEP (OR = 4.0, 95%CI = 1.5–10.5) were positively associated with willingness to prescribe PrEP on univariable analysis. The latter two were the strongest predictors on multivariate analysis. Participants cited cost and efficacy as major concerns. 75.3% did not feel that information had been adequately disseminated among physicians. In summary, Canadian physicians demonstrate varying levels of support for PrEP and express concerns about its implementation. Further research on real-world effectiveness, continuing medical education, and clinical support is needed to prepare physicians for this prevention strategy.